Divine Aleru, Microbiome Signatures Research Coordinator

This study demonstrates that engineered E. coli Nissle 1917 can selectively colonize colorectal adenomas and reduce tumor burden in mice. The probiotic also shows promise for non-invasive detection and treatment of CRC in humans, suggesting a novel therapeutic and diagnostic platform.

Escherichia coli Nissle 1917 (EcN) shows promise as a tumour-targeting probiotic bacterium for cancer treatment and detection. This review investigates its tumour-homing abilities and outlines future research directions to optimize its use in clinical oncology.

This review analyzes the advancements in preventing urinary catheter-related infections (CAUTIs) through scientific publications and patents, highlighting innovations like antimicrobial-coated catheters and biofilm-resistant materials, with implications for clinical practice and healthcare systems.

Probiotic Escherichia coli Nissle 1917 iron competition reduced Salmonella in inflamed murine gut by using lipocalin-2–resistant siderophores and by dampening mucosal inflammation, showing a nutritional immunity route for probiotic therapy.

Escherichia coli Nissle 1917 acute diarrhoea therapy in infants and toddlers shortened illness from 4.8 to 2.5 days, raised response to 94.5%, and was as safe as placebo.

Escherichia coli Nissle 1917 improved IBS modestly overall but clearly in postinfectious or postantibiotic IBS, was as safe as placebo, and fits a dysbiosis-linked microbiome signature that needs 10–12 weeks of therapy to show.

Escherichia coli Nissle 1917 (EcN) significantly enhances protection against human rotavirus in gnotobiotic pigs by modulating plasmacytoid dendritic cells and NK cell responses, suggesting its potential as an effective probiotic treatment for viral gastroenteritis.

Escherichia coli Nissle 1917 (EcN) is a safe and effective probiotic for maintaining remission in ulcerative colitis patients, with clinical trial evidence showing equivalence to mesalazine in relapse prevention. Its mechanisms include immune modulation, antimicrobial activity, and gut barrier reinforcement.

Escherichia coli Nissle 1917 (EcN) interferes with the invasion of human intestinal epithelial cells by various pathogens through a secreted component, not by microcins or physical contact, suggesting its potential as a therapeutic probiotic to prevent gastrointestinal infections.

This study uncovers the dual role of Escherichia coli Nissle 1917, where its beneficial antibacterial activity is linked to the ClbP protein, while its genotoxic effects are dependent on colibactin. Engineering strains that decouple these activities could lead to safer probiotic therapies.

The study explores how Escherichia coli Nissle 1917’s microcins mediate competition in the inflamed gut, showing potential for therapeutic use in enterobacterial infections and colitis management.

E. coli Nissle uses yersiniabactin to bind zinc, overcome calprotectin, and colonize the inflamed gut, defining a metal-driven microbiome signature linked to Enterobacteriaceae dominance in colitis, with clear dependence on inflammation and pH.

Probiotic-e-coli-nissle-1917 shows benefit in ulcerative colitis, infant diarrhea, and innate immune priming, with transient engraftment and microcin-based pathogen suppression, but no effect in Crohn’s disease. Safety is strong, though neonatal products require caution.

E. coli Nissle 1917 is a non-pathogenic probiotic strain that inhibits pathogenic bacteria, reduces inflammation, and strengthens intestinal barrier function, with proven clinical efficacy in treating gastrointestinal diseases.

This study evaluates the inhibitory effects of Escherichia coli Nissle 1917 (EcN) on Clostridium perfringens type A, focusing on growth inhibition, toxin production, biofilm formation, and inflammatory cytokine responses in vitro.

Escherichia coli Nissle 1917 (EcN), a probiotic with a rich history, is now being engineered for therapeutic uses beyond gastrointestinal health, including metabolic disease treatment and immune modulation. Its potential in microbiome research and live vaccine development is also being explored.

Copper serves as both a vital nutrient and a potential toxin, with its regulation having profound effects on microbial pathogenesis and immune responses. In the body, copper interacts with pathogens, either supporting essential enzyme functions or hindering microbial growth through its toxicity. The gastrointestinal tract, immune cells, and bloodstream are key sites where copper plays a crucial role in controlling infection and maintaining microbial balance. Understanding copper’s interactions with the microbiome and host defenses allows for targeted clinical strategies.

Cadmium (Cd) is a highly toxic heavy metal commonly found in industrial, agricultural, and environmental settings. Exposure to cadmium can occur through contaminated water, food, soil, and air, and it has been linked to a variety of health issues, including kidney damage, osteoporosis, and cancer. In agriculture, cadmium is often present in phosphate fertilizers and can accumulate in plants, entering the food chain. Its toxicity to living organisms makes cadmium a subject of regulatory concern worldwide, particularly in industrial waste disposal and environmental monitoring.

Lead exposure has a profound effect on the microbiome, disrupting microbial diversity, immune responses, and contributing to the development of antimicrobial resistance (AMR). Understanding how Pb interacts with microbial communities and impacts host-pathogen dynamics is essential for clinicians to mitigate long-term health risks and improve treatment strategies.

Arsenic can disrupt both human health and microbial ecosystems. Its impact on the gut microbiome can lead to dysbiosis, which has been linked to increased disease susceptibility and antimicrobial resistance. Arsenic’s ability to interfere with cellular processes, especially through its interaction with essential metals like phosphate and zinc, exacerbates these effects.

The study discusses dietary strategies to counteract the toxicity of cadmium and lead exposure, emphasizing the role of essential metals, vitamins, probiotics, and edible plants. These strategies offer a safer, more accessible alternative to traditional chelation therapy.

The study emphasizes the potential benefits of zinc and multi-mineral supplementation in reducing cadmium toxicity. It links cadmium exposure to various health issues and suggests supplementation as a strategy to mitigate its harmful effects.

The review examines how cadmium exposure affects gut microbiota, leading to dysbiosis, increased gut permeability, and systemic inflammation. It also explores the potential of probiotics to mitigate cadmium-induced toxicity, suggesting new therapeutic strategies.

This study shows that cadmium exposure disrupts gut function in zebrafish, affecting villi morphology, goblet cell mucus production, and glycoprotein distribution. These changes may impair gut defense and highlight the environmental risks of cadmium contamination.